Recent Research Progress in the Management of High-Altitude Pulmonary Hypertension (HAPH)
Han Hua, Liu Yanmin, Yu Bing
Qinghai University Qinghai Provincial Peoples Hospital
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
High-altitude pulmonary hypertension (HAPH) is a life-threatening disorder caused by hypobaric hypoxia at high altitudes. This review summarizes the latest advances in the pathogenesis and management of HAPH. The pathogenesis mainly involves hypobaric hypoxia, persistent pulmonary arteriolar constriction, smooth muscle cell proliferation, and vascular remodeling. Current therapeutic strategies include pharmacotherapy (PDE-5 inhibitors, endothelin receptor antagonists, prostacyclins, traditional Chinese medicine, and Tibetan medicine), oxygen therapy, and surgical interventions such as pulmonary arterial denervation and transplantation. This paper aims to provide updated evidence and clinical insights for the prevention and treatment of HAPH in high-altitude residents and travelers.
逐年被引趋势
暂无年度引用数据
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学High Altitude and Hypoxia
Pulmonary Hypertension Research and Treatments · Cardiovascular and Diving-Related Complications